Eli D Scher1, Paul B Romesser1, Christine Chen1, Felix Ho1, Yen Wuu1, Eric J Sherman2, Matthew G Fury2, Richard J Wong3, Sean McBride1, Nancy Y Lee4, Nadeem Riaz1. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, United States. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States. 3. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, United States. 4. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, United States. Electronic address: leen2@mskcc.org.
Abstract
OBJECTIVES: While surgery with or without adjuvant radiation therapy (RT) is the standard of care for oral cavity cancer (OCC), a select group requires nonsurgical treatment. We provide a single-institution experience using definitive chemotherapy and RT for primary OCC. MATERIALS AND METHODS: We examined 73 patients with previously untreated, non-metastatic primary OCC treated definitively from 1990 to 2011. There were 39 male and 34 female, with a median age of 63 years (range, 35-89). The disease distribution was Stage I and II (7% each), Stage III (14%), and Stage IV (73%). Oral tongue was the most common (48%), followed by floor of mouth (19%), retromolar trigone (13.7%), and others (8.2%). Median tumor dose was 70 Gy. Sixty-two percent of patients (n=45) were treated with concurrent chemotherapy, predominantly platinum-based. RESULTS: Median follow-up among surviving patients was 73.1 months (interquartile range 14.2-81.4 months). Actuarial 5-year overall survival was 15%. Incidences of locoregional and distant failures were 41.1% and 20.5%, respectively. Kaplan-Meier estimated 5-year rates of locoregional control and freedom from distant metastasis were 37% and 70%, respectively. Mucositis was the most common ⩾Grade 3 acute toxicity (49%). Incidences of Grade 3 late dysphagia and trismus were 15% and 13%, respectively. CONCLUSION: This study demonstrates over 20 years of experience using definitive chemoradiation for OCC at our institution. Our results illustrate the challenges in treating patients with advanced disease who are not surgical candidates, and the need for adequate and early treatment to prevent distant disease and improve survival outcomes.
OBJECTIVES: While surgery with or without adjuvant radiation therapy (RT) is the standard of care for oral cavity cancer (OCC), a select group requires nonsurgical treatment. We provide a single-institution experience using definitive chemotherapy and RT for primary OCC. MATERIALS AND METHODS: We examined 73 patients with previously untreated, non-metastatic primary OCC treated definitively from 1990 to 2011. There were 39 male and 34 female, with a median age of 63 years (range, 35-89). The disease distribution was Stage I and II (7% each), Stage III (14%), and Stage IV (73%). Oral tongue was the most common (48%), followed by floor of mouth (19%), retromolar trigone (13.7%), and others (8.2%). Median tumor dose was 70 Gy. Sixty-two percent of patients (n=45) were treated with concurrent chemotherapy, predominantly platinum-based. RESULTS: Median follow-up among surviving patients was 73.1 months (interquartile range 14.2-81.4 months). Actuarial 5-year overall survival was 15%. Incidences of locoregional and distant failures were 41.1% and 20.5%, respectively. Kaplan-Meier estimated 5-year rates of locoregional control and freedom from distant metastasis were 37% and 70%, respectively. Mucositis was the most common ⩾Grade 3 acute toxicity (49%). Incidences of Grade 3 late dysphagia and trismus were 15% and 13%, respectively. CONCLUSION: This study demonstrates over 20 years of experience using definitive chemoradiation for OCC at our institution. Our results illustrate the challenges in treating patients with advanced disease who are not surgical candidates, and the need for adequate and early treatment to prevent distant disease and improve survival outcomes.
Authors: Aaron W Pederson; Joseph K Salama; Mary Ellen Witt; Kerstin M Stenson; Elizabeth A Blair; Everett E Vokes; Daniel J Haraf Journal: Am J Clin Oncol Date: 2011-08 Impact factor: 2.339
Authors: Volker Budach; Martin Stuschke; Wilfried Budach; Michael Baumann; Dirk Geismar; Gerhard Grabenbauer; Ingrid Lammert; Klaus Jahnke; Georg Stueben; Thomas Herrmann; Michael Bamberg; Peter Wust; Wolfgang Hinkelbein; Klaus-Dieter Wernecke Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544
Authors: Alyson Bessell; Anne-Marie Glenny; Susan Furness; Jan E Clarkson; Richard Oliver; David I Conway; Michaelina Macluskey; Sue Pavitt; Philip Sloan; Helen V Worthington Journal: Cochrane Database Syst Rev Date: 2011-09-07
Authors: Merav A Ben-David; Maximiliano Diamante; Jeffrey D Radawski; Karen A Vineberg; Cynthia Stroup; Carol-Anne Murdoch-Kinch; Samuel R Zwetchkenbaum; Avraham Eisbruch Journal: Int J Radiat Oncol Biol Phys Date: 2007-02-22 Impact factor: 7.038
Authors: J L Giralt; J Gonzalez; J M del Campo; J Maldonado; X Sanz; J Pamias; A Eraso; S Bescos; G Raspall Journal: Cancer Date: 2000-09-01 Impact factor: 6.860
Authors: Curtis R Pickering; Jiexin Zhang; Suk Young Yoo; Linnea Bengtsson; Shhyam Moorthy; David M Neskey; Mei Zhao; Marcus V Ortega Alves; Kyle Chang; Jennifer Drummond; Elsa Cortez; Tong-Xin Xie; Di Zhang; Woonbok Chung; Jean-Pierre J Issa; Patrick A Zweidler-McKay; Xifeng Wu; Adel K El-Naggar; John N Weinstein; Jing Wang; Donna M Muzny; Richard A Gibbs; David A Wheeler; Jeffrey N Myers; Mitchell J Frederick Journal: Cancer Discov Date: 2013-04-25 Impact factor: 39.397
Authors: Kerstin M Stenson; Rangesh Kunnavakkam; Ezra E W Cohen; Louis D Portugal; Elizabeth Blair; Daniel J Haraf; Joseph Salama; Everett E Vokes Journal: Laryngoscope Date: 2010-01 Impact factor: 3.325
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Gabriela Studer; Michelle Brown; Marius Bredell; Klaus W Graetz; Gerhard Huber; Claudia Linsenmeier; Yousef Najafi; Oliver Riesterer; Tamara Rordorf; Stephan Schmid; Christoph Glanzmann Journal: Radiat Oncol Date: 2012-06-11 Impact factor: 3.481
Authors: Michael T Spiotto; Gina Jefferson; Barry Wenig; Michael Markiewicz; Ralph R Weichselbaum; Matthew Koshy Journal: JAMA Otolaryngol Head Neck Surg Date: 2017-07-01 Impact factor: 6.223
Authors: Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger Journal: J Clin Oncol Date: 2019-02-27 Impact factor: 44.544
Authors: Muhammad Faisal; Taskheer Abbas; Usman Khaleeq; Mohammad Adeel; Abdul Wahid Anwer; Raza Hussain; Arif Jamshed Journal: Cureus Date: 2017-05-01
Authors: Kristin Lang; Melissa Baur; Thomas Held; Rami El Shafie; Julius Moratin; Christian Freudlsperger; Karim Zaoui; Nina Bougatf; Jürgen Hoffmann; Peter K Plinkert; Jürgen Debus; Sebastian Adeberg Journal: Radiol Oncol Date: 2021-11-19 Impact factor: 2.991